Search Results
Your search for Matthew Stenger matches 7842 pages
Showing 7601 - 7650No Survival Difference for Autologous vs Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Chemotherapy-Sensitive Mantle Cell Lymphoma
In an analysis reported in the Journal of Clinical Oncology, Fenske et al compared outcomes with early or late autologous vs reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in a population of patients with chemotherapy-sensitive mantle cell lymphoma. They found no...
Phase II Pilot Study Does Not Support Phase III Investigation of IV High-Dose Interferon Without Maintenance in Resected Melanoma
There is evidence that high-dose interferon alfa-2b consisting of 4 weeks of daily intravenous interferon alfa-2b followed by 48 weeks of subcutaneous maintenance interferon alfa-2b three times per week reduces risk of recurrence of resected melanoma and that response may depend on the early...
Study Evaluates Risk of Depression by Race and Sex Among Patients With Newly Diagnosed Lung Cancer
In a study reported in the Journal of Clinical Oncology, Traeger et al evaluated risk of depression symptoms and psychosocial service use by race and sex among patients with newly diagnosed lung cancer. The investigators found that black men have the highest prevalence of depressive symptoms, white ...
No Difference for Aprepitant vs Dexamethasone for Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer
In a phase III study reported in the Journal of Clinical Oncology, Roila et al compared aprepitant vs dexamethasone in prevention of delayed emesis in breast cancer patients treated with anthracycline/cyclophosphamide who had received palonosetron/aprepitant/dexamethasone prophylaxis for acute...
Imiquimod 5% Cream Inferior to Surgical Excision in Nodular and Superficial Basal Cell Carcinoma
In a noninferiority trial (SINS) reported in The Lancet Oncology, Bath-Hextall et al compared imiquimod 5% cream vs surgical excision for nodular and superficial basal cell carcinomas. Imiquimod cream was found to be inferior to surgical excision, but it may have a role in treatment of low-risk...
Neoadjuvant Paclitaxel Before Anthracycline Improves Response in High-Risk Early Breast Cancer
In a phase III 2×2 factorial trial (Neo-tAnGo) reported in The Lancet Oncology, Earl et al compared neoadjuvant therapy with epirubicin/cyclophosphamide followed by paclitaxel with or without gemcitabine vs paclitaxel with or without gemcitabine followed by epirubicin/cyclophosphamide in ...
Oral Ibandronic Acid Is Not Noninferior to IV Zoledronic Acid in Preventing Skeletal-Related Events in Patients With Breast Cancer
In a phase III noninferiority trial (ZICE) reported in The Lancet Oncology, Barrett-Lee et al compared oral ibandronic acid vs intravenous zoledronic acid in treatment of bone metastases from breast cancer. The study showed that ibandronic acid was not noninferior to zoledronic acid in preventing...
Sustained Complete Responses With Novel Immunotherapy in Lymphoma
Approximately 40% of patients with Hodgkin or non-Hodgkin lymphoma have tumor cells that express the type II latency Epstein-Barr virus (EBV) antigens latent membrane protein 1 (LMP1) and LMP2. T cells specific for these antigens are present in low levels and may be rendered nonreactive by the...
Low-Dose CT Screening May Result in Overdiagnosis of Lung Cancer
In a study reported in JAMA Internal Medicine, Patz et al of the NLST Overdiagnosis Manuscript Writing Team estimated the magnitude of overdiagnosis using low-dose computed tomography (CT) screening for lung cancer in the National Lung Screening Trial (NLST). They estimated that more than 18% of...
Anti–PD-1 Antibody Pidilizumab Plus Rituximab Shows High Activity in Relapsed Follicular Lymphoma
Antitumor immune responses may be inhibited by immune checkpoints in the tumor microenvironment including effects of PD-1 (programmed cell death 1), a co-inhibitory receptor on tumor T cells that impairs T-cell function. In a phase II study reported in The Lancet Oncology, Westin et al assessed the ...
No Survival Benefit for Tecemotide After Chemoradiotherapy in Stage III NSCLC
In the phase III START trial reported in The Lancet Oncology, Butts et al assessed whether maintenance treatment with the MUC1 antigen–specific immunotherapy tecemotide could prolong overall survival in patients with unresectable stage III non–small cell lung cancer (NSCLC) who had...
EUROCARE-5: Trends in Survival for Childhood Cancers
As reported in The Lancet Oncology by Gatta et al, the population-based EUROCARE-5 study has shown improved survival for all childhood cancers combined in Europe between 1999–2001 and 2005–2007 and persistence of regional survival disparities. Study Details The study involved analysis ...
EUROCARE-5 Shows Increased Cancer Survival and Persisting Regional Disparities
As reported in The Lancet Oncology by De Angelis et al, the population-based EUROCARE-5 study has shown improved cancer survival over time in all European regions, although regional disparities remain. Study Details In this retrospective observational study, data from 107 cancer registries...
Younger Women With Younger Children Less Likely to Receive Radiation Therapy After Breast-Conserving Surgery for Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Pan et al assessed factors associated with noncompliance with recommended radiation therapy following breast-conserving surgery for breast cancer. A primary factor in underuse of radiation therapy was younger patients having...
No Overall Survival Benefit With Addition of Sunitinib to Prednisone in Metastatic Castration-Resistant Prostate Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Michaelson et al assessed the addition of the antiangiogenesis agent sunitinib (Sutent) to prednisone in patients with progressive metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. No...
Low hENT1 Is Associated With Poorer Survival in Patients With Pancreatic Cancer Receiving Adjuvant Gemcitabine
In a study reported in the Journal of the National Cancer Institute, Greenhalf et al analyzed the association between human equilibrative nucleoside transporter 1 (hENT1) levels and survival in patients with pancreas cancer receiving adjuvant gemcitabine or fluorouracil (5-FU)/leucovorin after ...
Suboptimal Adverse Event Reporting in Cancer Clinical Trial Publications
In a study reported in the Journal of Clinical Oncology, Sivendran et al assessed the degree to which publication of phase III trials in oncology conformed with CONSORT (Consolidated Standards of Reporting Trials) recommendations for reporting adverse events. They found that adverse event...
Protective Effect of Aspirin for Colorectal Cancer Is Associated With rs6983267 T Allele
It has been posited that aspirin treatment may reduce risk for colorectal cancer through inhibition of WNT/cadherin-associated protein β1 (CTNNB1, or β-catenin) signaling. In a study reported in the Journal of the National Cancer Institute, Nan et al investigated the potential role of the ...
Final Overall Survival Analysis of CONFIRM Trial Shows Advantage of Higher Dose of Fulvestrant in Advanced Breast Cancer
As reported in the Journal of the National Cancer Institute by Di Leo et al, the final overall survival analysis of the CONFIRM trial has shown a significant benefit of fulvestrant (Faslodex) at 500 mg vs 250 mg in postmenopausal women with locally advanced or metastatic estrogen...
No Benefit of Calcium/Magnesium in Preventing Oxaliplatin-Induced Sensory Neurotoxicity in Patients With Colon Cancer
In a phase III N08CB/Alliance trial reported in the Journal of Clinical Oncology, Loprinzi et al assessed whether calcium and magnesium treatment reduced oxaliplatin-related neurotoxicity in patients with colon cancer receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin). They found ...
Survival Benefit With High-Dose Cytarabine Induction in AML Patients Aged < 46 Years
In a European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell’ Adulto (GIMEMA) phase III trial (AML-12) reported in Journal of Clinical Oncology, Willemze et al compared induction regimens containing high-dose or standard-dose...
Increased Cardiovascular Risk Despite Healthier Lifestyle Characteristics in Hematopoietic Cell Transplant Survivors
In a study reported in the Journal of Clinical Oncology, Chow et al compared cardiovascular risk and risk factors in hematopoietic cell transplantation recipients with those in a matched general population sample. Hematopoietic cell transplantation survivors were at greater risk for cardiomyopathy, ...
Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rate in Initial Therapy for Follicular Lymphoma
In a phase II trial reported in the Journal of Clinical Oncology, Illidge et al evaluated radioimmunotherapy with fractionated 90Y-ibritumomab tiuxetan (Zevalin) as initial treatment in patients with mostly advanced follicular lymphoma. The treatment was well tolerated, with manageable...
No Difference in PFS for Temsirolimus vs Sorafenib as Second-Line Therapy After Sunitinib in Metastatic RCC
In the phase III INTORSECT trial reported in the Journal of Clinical Oncology, Hutson et al compared temsirolimus (Torisel) vs sorafenib (Nexavar) as second-line treatment in patients with metastatic renal cell carcinoma after progression on sunitinib (Sutent). There was no significant difference...
No Difference Between Temsirolimus/Bevacizumab vs Interferon Alfa/Bevacizumab in First-Line Therapy for Metastatic Renal Cell Carcinoma
In the phase III INTORACT trial reported in the Journal of Clinical Oncology, Rini et al compared temsirolimus (Torisel)/bevacizumab (Avastin) vs interferon alfa/bevacizumab in first-line treatment of metastatic renal cell carcinoma. There were no significant differences between the two regimens in ...
Study Explores Risk of New Primary Melanomas After Diagnosis of Stage III/IV Melanoma in Patients Not Receiving BRAF Inhibitors
In a study reported in the Journal of Clinical Oncology, Zimmer et al assessed the incidence of spontaneous new primary melanomas in patients with stage III or IV melanoma in order to help clarify risk of BRAF inhibitor–related new melanomas. They found that patients not receiving BRAF...
Elevated Plasma Vitamin B12 Levels Associated With Cancer Risk
High plasma levels of vitamin B12 (cobalamin) have been reported in patients with cancer of different types. In a Danish study reported in the Journal of the National Cancer Institute, Arendt et al assessed cancer risk in subjects presenting with elevated cobalamin. They found that cancer risk...
Circulating Inflammation Markers Associated With Risk of Lung Cancer
In a study reported in the Journal of the National Cancer Institute, Shiels et al identified 11 circulating inflammation markers significantly associated with lung cancer risk. A risk score using four of the markers distinguished risk levels among current and former smokers. Study Details This...
Preoperative MRI Assessment of Circumferential Resection Margin Predicts Survival and Local Recurrence in Rectal Cancer
In a study reported in the Journal of Clinical Oncology, Taylor et al evaluated the ability of preoperative high-resolution magnetic resonance imaging (MRI) assessment of circumferential resection margin to predict outcome in patients with rectal cancer. They found that MRI assessment was...
Eight-Gene Profile Predicts Benefit of Adjuvant Trastuzumab in HER2-Negative Disease
The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial suggested that efficacy of adjuvant trastuzumab (Herceptin) extended to patients with HER2-negative breast cancer. In a study reported in the Journal of the National Cancer Institute, Pogue-Geile et al identified and...
PPM1D Mutations in Circulating White Blood Cells Associated With Risk of Ovarian Cancer, Increased Mortality, and Risk of Breast Cancer
In a brief communication published in the Journal of the National Cancer Institute, Akbari et al reported finding a higher frequency of PPM1D mutations in circulating white blood cells from women with ovarian cancer vs controls, higher mortality associated with the mutation in women with ovarian...
Nonsignificant Survival Benefit With Postoperative Radiation Therapy for Head and Neck Cancer at Academic Center vs Other Institutions
In a study reported in JAMA Otolaryngology Head & Neck Surgery, George et al evaluated radiation treatment characteristics and outcomes among head and neck squamous cell carcinoma patients receiving adjuvant external-beam radiation therapy at an academic center vs other institutions....
Maintained Oral Intake and Swallowing Exercise Adherence During Radiation Therapy Improve Long-Term Swallowing Outcomes for Pharyngeal Cancer Patients
In a study reported in JAMA Otolaryngology Head & Neck Surgery, Hutcheson et al assessed the effects of maintained oral intake and adherence to swallowing exercises during radiation therapy or chemoradiation therapy for pharyngeal cancer. They found that both practices contributed independently ...
Nurse Navigators Improve Patient-Reported Quality of Care in Early Cancer Care
In a study reported in the Journal of Clinical Oncology, Wagner et al assessed whether a nurse navigator intervention improved quality of life or patient experience with care in patients who recently received a diagnosis of breast, colorectal, or lung cancer. Although no differences in...
Postradiotherapy Neck Dissection Improves Local Control in Head and Neck Squamous Cell Carcinoma Patients With Advanced Nodal Disease
Available data indicate that lymph node involvement predicts failure at primary and distant sites after chemoradiation for head and neck cancer. In a study reported in JAMA Otolaryngology Head & Neck Surgery, Ranck et al assessed the impact of postradiotherapy neck dissection on local and...
Thyroid Ultrasound Strategy Identifies Low-Risk Patients Who Can Defer Biopsy
In a study reported in JAMA Internal Medicine, Smith-Bindman et al evaluated the ability of ultrasound imaging characteristics to determine risk of thyroid cancer associated with thyroid nodules. They found that a strategy of using two abnormal nodule characteristics as an indication for biopsy...
Reduced Specialist Consultation and Multimodality Therapy May Account for Poorer Survival in Black Patients With Metastatic Colorectal Cancer
Black patients with metastatic colorectal cancer have been found to have poorer survival than white patients. In a study reported in Journal of the National Cancer Institute, Simpson et al found that black patients were less likely to have specialist consultations and to receive multimodality...
ASCO Endorses Cancer Care Ontario Guideline for Follow-up in Colorectal Cancer Survivors
ASCO has policy and procedures for endorsing clinical practice guidelines developed by other professional organizations. As reported in the Journal of Clinical Oncology by Meyerhardt et al of the ASCO Clinical Practice Guidelines Committee, ASCO has endorsed the Cancer Care Ontario (CCO)...
Further Improvement Needed in Breast MRI Use in Community Practice
In a study reported in JAMA Internal Medicine, Wernli et al evaluated use of breast magnetic resonance imaging (MRI) in the community setting from 2005 to 2009. They found that although recommended use of MRI for screening of high-risk women is increasing, considerable progress is needed in...
Increase in Breast MRIs Does Not Reflect Recommendations for Appropriate Use
In a study reported in JAMA Internal Medicine, Stout et al assessed use of breast magnetic resonance imaging (MRI) in the community setting from 2000 to 2011. They found a steep increase in use in screening and surveillance, with most women not meeting American Cancer Society (ACS) criteria for...
PIK3CA Mutation Fails to Predict Outcome of Irinotecan-Based Therapy in Stage III Colon Cancer
In a study reported in Journal of the National Cancer Institute, Shuji Ogino, MD, PhD, of Dana-Farber Cancer Institute and Harvard Medical School, and colleagues from the Alliance for Clinical Trials in Oncology evaluated the association of PIK3CA mutations with outcome in patients with stage III...
Increasing Proportion of Head and Neck Cancer Patients Treated at Teaching Hospitals
In a study reported in JAMA Otolaryngology Head & Neck Surgery, Neil Bhattacharyya, MD, of Brigham and Women’s Hospital and Harvard Medical School, and Elliot Abemayor, MD, PhD, of David Geffen School of Medicine at UCLA, analyzed recent patterns of hospitalization for head and neck...
12-Gene Recurrence Score Independently Predicts Recurrence in Patients With Stage II/III Colon Cancer
In a study reported in Journal of Clinical Oncology, Greg Yothers, PhD, of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Biostatistical Center and the University of Pittsburgh Graduate School of Public Health, and colleagues assessed performance of the 12-gene colon cancer...
Brentuximab Vedotin Plus ABVD or AVD Is Highly Active in Newly Diagnosed Hodgkin Lymphoma
Brentuximab vedotin (Adcetris) is active in patients with relapsed/refractory Hodgkin’s lymphoma. In a phase I study reported in The Lancet Oncology, Anas Younes, MD, of Memorial Sloan-Kettering Cancer Center (formerly of The University of Texas MD Anderson Cancer Center), and colleagues...
MicroRNA Signature Predicts Risk of Recurrence After Surgery for Stage II Colon Cancer
In a study reported in The Lancet Oncology, Jia-Xing Zhang, MD, of Sun Yat-sen University, and colleagues identified a six-microRNA (miRNA) signature that predicted risk of recurrence after surgery for stage II colon cancer and that may help to identify patients most likely to benefit from adjuvant ...
Predictors of Sentinel Lymph Node Metastasis Identified in Thin Melanomas
In a study reported in the Journal of Clinical Oncology, Dale Han, MD, of Moffitt Cancer Center, and colleagues in the Sentinel Lymph Node Working Group attempted to identify factors predictive of sentinel lymph node metastasis in thin melanomas. They found that Breslow thickness ≥ 0.75 mm, ...
STAT3 Activation Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP
In a study reported in the Journal of Clinical Oncology, Xin Huang, PhD, of the National Clinical Research Center of Cancer in Tianjin, and colleagues investigated whether STAT3 activation can identify patients with diffuse large B-cell lymphoma treated with R-CHOP (rituximab [Rituxan] plus...
Targeted Intraoperative Radiotherapy Concurrent With Lumpectomy Noninferior to External-Beam Radiotherapy in Preventing Local Breast Cancer Recurrence
In a randomized noninferiority trial (TARGIT-A) reported in The Lancet, Jayant S. Vaidya, PhD, and Michael Baum, MD, of University College London, and colleagues compared risk-adapted radiotherapy using single-dose targeted intraoperative radiotherapy vs fractionated external-beam radiotherapy in...
No Advantage of Concurrent vs Sequential Trastuzumab/Anthracycline Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
In the phase III Z1041 trial reported in The Lancet Oncology, Aman U. Buzdar, MD, of The University of Texas MD Anderson Cancer Center, and colleagues compared neoadjuvant therapy with FEC-75 (fluorouracil [5-FU], epirubicin, and cyclophosphamide) followed by paclitaxel plus trastuzumab (Herceptin) ...
Prognostic Model Predicts Metastatic Castration-Resistant Prostate Cancer Survival in Second-Line Chemotherapy After Docetaxel
In a study reported in the Journal of the National Cancer Institute, Susan Halabi, MD, of Duke University Medical Center, and colleagues developed and validated a prognostic model predicting prostate cancer survival in patients receiving second-line chemotherapy for castration-resistant...
